

BQ-3020

Cat. No.:	HY-P1016
CAS No.:	143113-45-5
Molecular Formula:	C ₉₆ H ₁₄₀ N ₂₀ O ₂₅ S
Molecular Weight:	2006.32
Sequence:	Ac-Leu-Met-Asp-Lys-Glu-Ala-Val-Tyr-Phe-Ala-His-Leu-Asp-Ile-Ile-Trp
Sequence Shortening:	Ac-Acetyl-LMDKEAVYFAHLDIIW
Target:	Endothelin Receptor
Pathway:	GPCR/G Protein
Storage:	Please store the product under the recommended conditions in the Certificate of Analysis.

BIOLOGICAL ACTIVITY

Description	BQ-3020 is a selective endothelin receptor (ET _B receptor) agonist that displaces [¹²⁵ I] ET-1 binding to ET _B receptors, with an IC ₅₀ value of 0.2 nM. BQ-3020 elicits vasoconstriction in the rabbit pulmonary artery. BQ-3020 makes relaxation of the pig urinary bladder neck and can be used for cardiovascular disease research ¹² .									
IC₅₀ & Target	ET _B 0.2 nM (IC ₅₀)									
In Vitro	<p>BQ-3020 (0.01–300 nM, 7 min), produced concentration-dependent relaxationso on PhE-precontracted urothelium-denuded strips^[1].</p> <p>BQ-3020 (0.01–200 nM, 20 min) causes potent dose-dependent vasoconstriction with EC₅₀ values of 0.57nM in rabbit pulmonary arteries by inhibiting ETB receptors^[2].</p> <p>MCE has not independently confirmed the accuracy of these methods. They are for reference only.</p>									
In Vivo	<p>BQ-3020 (3 mg/kg for i.h., single dose) attenuates cancer pain by approximately 50% up to 3 h post-injection compared to PBS-vehicle and contralateral injection in cancer pain mouse model^[3].</p> <p>MCE has not independently confirmed the accuracy of these methods. They are for reference only.</p> <table border="1"> <tr> <td>Animal Model:</td> <td>Cancer pain mouse model ^[3]</td> </tr> <tr> <td>Dosage:</td> <td>3 mg/kg</td> </tr> <tr> <td>Administration:</td> <td>Injected subcutaneously at the site of the greatest tumor development</td> </tr> <tr> <td>Result:</td> <td>Attenuated cancer pain by approximately 50% up to 3 h post-injection compared to PBS-vehicle and contralateral injection</td> </tr> </table>		Animal Model:	Cancer pain mouse model ^[3]	Dosage:	3 mg/kg	Administration:	Injected subcutaneously at the site of the greatest tumor development	Result:	Attenuated cancer pain by approximately 50% up to 3 h post-injection compared to PBS-vehicle and contralateral injection
Animal Model:	Cancer pain mouse model ^[3]									
Dosage:	3 mg/kg									
Administration:	Injected subcutaneously at the site of the greatest tumor development									
Result:	Attenuated cancer pain by approximately 50% up to 3 h post-injection compared to PBS-vehicle and contralateral injection									

REFERENCES

[1]. Arteaga JL,et.al. Endothelin ET(B) receptors are involved in the relaxation to the pig urinary bladder neck. Neurourol Urodyn. 2012 Jun;31(5):688-94.

[2]. Ihara M, et.al. A novel radioligand [125I]BQ-3020 selective for endothelin (ETB) receptors. Life Sci. 1992;51(6):PL47-52.

[3]. Quang PN, et.al. Peripheral endothelin B receptor agonist-induced antinociception involves endogenous opioids in mice. Pain. 2010 May;149(2):254-262.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA